Peptides Of 3 To 100 Amino Acid Residues Patents (Class 530/300)
  • Patent number: 9914751
    Abstract: The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: March 13, 2018
    Assignees: Children's Medical Center Corporation, President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
    Inventors: Michael C. Carroll, Francis D. Moore, Jr., Herbert B. Hechtman
  • Patent number: 9914955
    Abstract: The present invention relates to a genetically encoded FRET-based biosensor to monitor the activity of matrix metalloproteinase 9 (MMP-9). MMP-9 is an extracellular acting endopeptidase implicated in both physiological and pathological processes. A genetically encoded FRET biosensor anchored in the cellular membrane allows studying the proteolytic activity of MMP-9 with high spatiotemporal resolution at the exact region of MMP-9 action on the cell. Applicability of the biosensor, both in vitro and in vivo in living cells, has been demonstrated by ratiometric analysis of cleavage of the biosensor by a purified auto-activating mutant of MMP-9.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: March 13, 2018
    Assignee: Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk
    Inventors: Michal Stawarski, Jakub Wlodarczyk, Leszek Kaczmarek
  • Patent number: 9902960
    Abstract: The present invention relates to antisense oligonucleotide (ASO) compositions and particularly to compositions and methods for the cytosolic delivery of antisense oligonucleotides (ASOs). Hybrid ASOs, part single-stranded and part double-stranded, are provided, hybridizing to form a double-stranded region that can non-covalently bond to nucleic-acid-binding protein regions. In this way, ASO::protein complexes may be produced that facilitate delivery of antisense DNA into target cells. Such complexes may be used to down-regulate gene expression in cells.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: February 27, 2018
    Inventors: Simon Clifford Wainwright Richardson, Paul Douglas Remane Dyer, John Carlton Mitchell
  • Patent number: 9896486
    Abstract: A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 20, 2018
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman, Goran Bauren
  • Patent number: 9890411
    Abstract: An immobilized enzymatic reactor can include a wall defining a chamber having an inlet and an outlet; a solid stationary phase covalently linked to an enzyme and disposed within the chamber; and a pressure modulator in fluid communication with the chamber and adapted to support continuous flow of a liquid sample comprising a polymer analyte through the inlet, over the solid stationary phase, and out of the outlet under a pressure between about 2,500 and 35,000 psi. In one example, the solid stationary phase includes inorganic/organic hybrid particles in an ultra performance liquid chromatography system, the enzyme is a protease, and the polymer analyte is a polypeptide. The immobilized enzymatic reactor can prepare an analyte for applications such as for hydrogen deuterium exchange mass spectrometry.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: February 13, 2018
    Inventors: Joomi Ahn, Moon Chul Jung, Kevin D. Wyndham
  • Patent number: 9885714
    Abstract: The invention relates to an immunological method for detecting an extra renal active infection by JC virus in a patient candidate for a treatment with an immunosuppressive treatment or during the course of this treatment.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: February 6, 2018
    Assignees: Assistance Publlque—Hopitaux de Paris, Universite Paris—Sud 11
    Inventor: Yassine Taoufik
  • Patent number: 9878003
    Abstract: A method for inhibiting cartilage degradation comprising administering to a subject a therapeutically effective amount of a polypeptide comprising or consisting of a Link_TSG6 polypeptide is disclosed.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: January 30, 2018
    Assignee: The University of Manchester
    Inventors: Anthony Day, Caroline Milner, Sheona Patricia Drummond
  • Patent number: 9873729
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 23, 2018
    Assignee: AFFIBODY AB
    Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löblom, Torbjörn Gräslund, Johan Seijsing
  • Patent number: 9872920
    Abstract: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: January 23, 2018
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Patent number: 9849190
    Abstract: A method of treating breast cancer is described, in which a peptide having cancer selective translocation function-doxoribicin conjugate is administered. The conjugate includes doxorubicin chemically linked to the N-terminus or C-terminus of a VEGF-binding protein transduction domain (VPTD) peptide represented as SEQ ID NO: 1, wherein the VPTD peptide and doxorubicin are linked to each other by a disulfide bond, and wherein the VPTD peptide binds specifically to vascular endothelial growth factor (VEGF) in tumor cells or tumor tissues.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: December 26, 2017
    Inventors: Yoon Jeong Park, Chong-Pyoung Chung, Jin Sook Suh, Yoon Jung Choi
  • Patent number: 9834585
    Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of the complement inhibitors in the treatment and prevention of diseases.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: December 5, 2017
    Assignee: Volution Immuni Pharmaceuticals SA
    Inventor: Miles Andrew Nunn
  • Patent number: 9830422
    Abstract: Systems, methods and computer-readable media are described herein for determining a protein's most-likely structural alignment. A maximum likelihood algorithm is utilized that compares possible input protein structural translocations with a template protein. It then calculates the optimally superimposed position for each input protein utilizing a distance-based probability scoring algorithm that accurately manages extreme distances.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: November 28, 2017
    Assignee: The Curators of the University of Missouri
    Inventors: Gerald Wyckoff, Scott Foy
  • Patent number: 9815882
    Abstract: Fusion polypeptides comprising a TRAIL trimer and a targeting domain are disclosed. The targeting domain can be, in some embodiments, a sequence that binds MUC16, which is prevalent on some tumor cells such as pancreatic and ovarian tumor cells. A sequence that binds MUC 16 can be mesothelin or a MUC16-binding fragment thereof, such as amino acids 1-64 of mesothelin. A fusion polypeptide of the present teachings can induce apoptosis in a target cell such as a MUC16-expressing cancer cell. Also disclosed are nucleic acids encoding the fusion polypeptides, and methods of use of the fusion polypeptides and nucleic acids.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: November 14, 2017
    Assignee: Washington University
    Inventors: Dirk Spitzer, William G Hawkins
  • Patent number: 9752151
    Abstract: The present invention relates to a composition for treatment or metastasis suppression of cancers which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. According to the present invention, the p34 protein knock-down causes monoubiquitination of PTEN and accordingly nuclear localization of PTEN is induced, as a result, an Akt pathway which is related to survival, proliferation, invasive properties and metastatic properties of tumors is inhibited, and thus there is an effect of significantly reducing clonogenic potential and tumor forming potential of various cancer cells which simultaneously express PTEN and NEDD4-1. Consequently, the p34 gene expression inhibitor or p34 protein activity inhibitor according to the present invention can be effectively used as a treatment agent or a metastasis suppression agent for cancers.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: September 5, 2017
    Assignees: The Asan Foundation, University of Ulsan Foundation for Industry Cooperation
    Inventors: Tae Won Kim, Dong Hoon Jin, Seung Woo Hong, Jai Hee Moon, Jae Sik Shin, Jin Sun Kim, Kyung Ah Jung, Jung Shin Lee, Eun Kyung Choi, Jae Lyun Lee, Yong Sang Hong, Kyu Pyo Kim, Ky Youb Nam, Bong Cheol Kim
  • Patent number: 9732137
    Abstract: A semi-recombinant method for the production of GLP-1 analogues and derivatives with non-proteogenic amino acids in the N-terminal part combining the use of recombinant expression techniques and chemical peptide synthesis.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: August 15, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Færgeman Lau, Asser Sloth Andersen, Paw Bloch, Jesper Lau, Patrick William Garibay, Thomas Kruse, Inga Sig Nielsen Nørby, Claus Ulrich Jessen, Caspar Christensen, Jens Christian Norrild
  • Patent number: 9724425
    Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: August 8, 2017
    Inventors: Beat Amrein, Stefan Foser, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
  • Patent number: 9688734
    Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: June 27, 2017
    Assignee: ALZINOVA AB
    Inventors: Torleif Härd, Anders Sandberg
  • Patent number: 9687832
    Abstract: The present invention provides a bifunctional catalyst of the formula (1): wherein: each R1 is independently selected from an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted aralkyl group and an optionally substituted alkaryl group; Z represents a divalent organic linking moiety optionally containing one or more stereocenters; and EWG represents an electron-withdrawing group.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: June 27, 2017
    Assignee: Oxford University Innovation Limited
    Inventors: Darren J. Dixon, Alistair J. Farley, Marta G. Núñez
  • Patent number: 9688857
    Abstract: A compound represented by the formula (I) (R1 represents hydrogen atom or a monovalent substituent; R2 and R3 represent hydrogen atom, an alkyl group, or a halogen atom; R4 and R5 represent an alkyl group or an aryl group; R6 and R7 represent hydrogen atom, an alkyl group, or a halogen atom; R8 represent hydroxy group or a dialkoxyboranetriyl group; and X represents silicon atom, germanium atom, or tin atom), which is a novel fluorophore usable as a mother nucleus of an off/on type fluorescent probe not utilizing the intramolecular photoinduced electron transfer.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: June 27, 2017
    Inventors: Tetsuo Nagano, Kenjiro Hanaoka, Yuichiro Koide, Takahiro Egawa, Kazuhisa Hirabayashi
  • Patent number: 9675679
    Abstract: The invention features immunoconjugates for impeding weight gain and treating obesity in a subject. The immuno-conjugates comprise particular ghrelin polypeptides and a suitable carrier moiety.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: June 13, 2017
    Assignee: The Scripps Research Institute
    Inventors: Eric P. Zorrilla, Michael M. Meijler, Kim D. Janda
  • Patent number: 9670258
    Abstract: Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone Morphogenic Protein. Uses of compounds of the present invention in the treatment of bone lesions, degenerative joint disease and to enhance bone formation are disclosed.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 6, 2017
    Assignees: Ferring B.V., Brookhaven Science Associates, LLC
    Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin, Takahashi Kazuyuki
  • Patent number: 9662372
    Abstract: The present invention is related to compositions and methods to treat, ameliorate and/or prevent morbidity and/or mortality from microbial infections. In particular, bacterial infections that are associated with the production and release of bacterial toxins. For example, many Clostridia bacteria, such as Clostridium difficile, release toxins resulting in tissue and organ damage and death, even after antibiotic therapy that either reduces or eliminates the bacteria. In particular, various peptides, polypeptides, and proteins are disclosed herein that either inactivate Clostridium difficile toxin and/or reduce Clostridium difficile toxin production.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: May 30, 2017
    Assignee: BIOLOG, Inc.
    Inventors: Barry Bochner, Xiang-He Lei
  • Patent number: 9644010
    Abstract: Isolated LY6K-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can be promiscuously bind to MHC class II molecules and induce LY6K-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: May 9, 2017
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
  • Patent number: 9622429
    Abstract: The invention relates to the use of a peptide comprising a six-member ring created by the disulfide bond between two cysteines in the increase of biomass of a photosynthetic organism, for its application in the wood industry, in obtaining energy coming from renewable sources and in agriculture.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: April 18, 2017
    Assignee: BioMass Booster, S.L.
    Inventors: Alfredo Martinez Ramirez, Jorge Conrado Arenas Vidal
  • Patent number: 9625453
    Abstract: The present invention provides a microporous membrane for detecting at least one target analyte in a sample. The membrane includes an array that comprises at least one capture element and the at least one control element printed on the membrane surface, the at least one capture element corresponding to and being able to bind a target analyte, the plurality of control elements, when present including: i) at least one fiduciary marker, ii) at least one negative control to monitor background signal, iii) at least one negative control to monitor assay specificity, iv) at least one positive colorimetric control, v) at least one positive control to monitor assay performance or any combination thereof.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: April 18, 2017
    Assignee: Pictor Limited
    Inventor: Sarita Kumble
  • Patent number: 9612246
    Abstract: Disclosed herein are methods for large-scale, high-throughput identification of protein-protein interactions and the topologies thereof under physiologically relevant conditions. In one aspect, the disclosure provides methods for identifying one or a plurality of interacting peptides within a biological system comprising obtaining a population of proteins cross-linked with a cleavable protein interaction reporter (PIR) cross-linker, cleaving the PIR crosslinker to produce released peptides and cleaved reporter ions, and analyzing the population of released peptides to identify interacting peptides. Also disclosed are methods for identifying candidate drug compounds, as well as methods of data processing and visualization of protein-protein interactions.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: April 4, 2017
    Assignee: University of Washington Though Its Center For Commercialization
    Inventors: James E. Bruce, Juan Chavez, Chad Weisbrod
  • Patent number: 9605025
    Abstract: Antagonist peptide of the bond between CD47 and a protein belonging to the thrombospondin family has the sequence S1 R1-R2-R3-S-Q-L-L-K-G-R4-R5-R6 and interacts specifically with the C-terminal end of the TSP, at the site of the bond between the TSP and the CD47 receptor. Interaction between the CD47 receptor and the protein is prevented. The peptide can be used in the context of cancer treatments.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: March 28, 2017
    Assignee: Universite de Reims Champagne Ardenne
    Inventors: Stéphane Dedieu, Nicolas Floquet, Laurent Martiny, Christophe Schneider, Albin Jeanne, Emilie Sick, Manuel Dauchez
  • Patent number: 9605344
    Abstract: An atomic layer deposition method is disclosed for preparing polypeptides. The method comprises providing a solid-phase support comprising a reactive amine monolayer in an atomic layer deposition (ALD) chamber. The solid-phase support is contacted with a first protected amino acid substituted with a protecting group by atomic layer deposition, wherein the protecting group is bonded to a non-side chain amino group of the protected amino acid. A carboxylic acid group of the first protected amino acid is reacted with the reactive amine monolayer, thereby coupling the first protected amino acid to the solid-phase support to produce a coupled-product.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: March 28, 2017
    Assignee: STC.UNM
    Inventors: Ying-Bing Jiang, Joseph L. Cecchi, Yaqin Fu, C. Jeffrey Brinker
  • Patent number: 9603941
    Abstract: Synthetic design of drug-incorporated novel dendrimer structures for quantitatively controlled drug delivery. The dendritic drugs have better control and thus a quantitative drug release can be obtained. There are no prior art dendritic drugs that control release both sequentially and quantitatively like the dendritic drugs disclosed herein. The dendritic drugs are formed by incorporating multiple same type drug units or more than two different drug types into a dendritic cascade structure to form a dendrimer drug.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: March 28, 2017
    Inventors: Minghui Chai, Schengzhuang Tang
  • Patent number: 9598466
    Abstract: Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: March 21, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Jianglong Zhu, Dongjoo Lee, Philip Livingston, Govind Ragupathi
  • Patent number: 9598486
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: March 21, 2017
    Inventors: Brendan Lee, Kuber T. Sampath
  • Patent number: 9593142
    Abstract: The present invention relates to ligation agents and their use in making an amide ligation product. Methods of making the ligation agents are also disclosed.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: March 14, 2017
    Assignee: New York University
    Inventors: Paramjit S. Arora, Monika Raj, Huabin Wu
  • Patent number: 9592287
    Abstract: Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: March 14, 2017
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Lanying Du
  • Patent number: 9562070
    Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: February 7, 2017
    Assignees: Board of Regents, The University of Texas System, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Constantin G. Ioannides, George E. Peoples
  • Patent number: 9539339
    Abstract: A therapeutic particle comprises a particle comprising one or more therapeutic agents and one or more fibrin-avid peptide variants attached to the surface of the particle. A method for magnetically targeting a therapeutic agent toward a device in a subject, such as a temporarily introduced magnetizable catheter or an implanted stent, comprises administering the therapeutic particles to the subject and generating a magnetic field, which targets the magnetic particles toward the device. The affinity peptide-modified therapeutic particles may comprise an effective amount of an anti-proliferative agent, such as paclitaxel, to inhibit or prevent in-stent restenosis.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: January 10, 2017
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Robert J. Levy, Michael Chorny
  • Patent number: 9534018
    Abstract: Described herein are melanocortin analogs having enhanced activity and transport.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: January 3, 2017
    Inventor: Kenneth Allen Gruber
  • Patent number: 9533037
    Abstract: The instant invention comprises a process of preparing a composition comprising directed sequence polymer (DSP) mixtures that act as epitopes and useful as vaccines, such DSP synthesized according to a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use as a vaccine, preferably for infectious agents that are immune evasive.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: January 3, 2017
    Assignee: Declion Holdings LLC
    Inventors: Dustan Bonnin, Eric Zanelli, Jeff Krieger, Thomas Mathers
  • Patent number: 9522185
    Abstract: The present invention provides antibodies that bind to human GFR?3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFR?3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFR?3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 20, 2016
    Inventors: Susan D. Croll, Lynn Macdonald, Andrew J. Murphy
  • Patent number: 9517275
    Abstract: Provided herein are compositions and methods for targeted drug delivery to prevent restenosis in the cardiovascular system. In particular, provided herein are nanoscale delivery vehicles for drugs that prevent proliferation and neointimal hyperplasia.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: December 13, 2016
    Assignee: Northwestern University
    Inventors: Melina R. Kibbe, Samuel I. Stupp, Tyson J. Moyer, Edward Moreira Bahnson
  • Patent number: 9505822
    Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: November 29, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Adam Silverman, Douglas Jones, Niv Papo
  • Patent number: 9499800
    Abstract: Provided herein are compounds, conjugates and methods for making lipid-chemically self-assembled nanorings (Lipid-CSANs) and using them to treat diseases and modify cell surfaces.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: November 22, 2016
    Assignee: Regents of the University of Minnesota
    Inventor: Carston R. Wagner
  • Patent number: 9486503
    Abstract: A medicinal composition for suppressing or preventing the metastasis of a malignant tumor, the composition comprising, as an active ingredient, at least one kind of vasoprotective agent selected from the following (i) to (iv): (i) angiotensin II receptor antagonist, (ii) HMG-CoA reductase inhibitor, (iii) ghrelin or its derivative, and (iv) adrenomedullin or its derivative; or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: November 8, 2016
    Assignees: Shionogi & Co., Ltd., National Cerebral and Cardiovascular Center
    Inventors: Kenji Kangawa, Hiroshi Hosoda, Takashi Nojiri
  • Patent number: 9476872
    Abstract: A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: October 25, 2016
    Inventor: Katsuki Naito
  • Patent number: 9469676
    Abstract: The application provides Fc fusion proteins having novel arrangements. In one embodiment, the application provides Fc fusion proteins comprising a 10Fn3 domain. In another embodiment, the application provides Fc fusion proteins comprising linkers derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: October 18, 2016
    Inventors: Ray Camphausen, Amna Saeed-Kothe, Jonathan Davis, Tracy S. Mitchell
  • Patent number: 9469670
    Abstract: Populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLNDSQ (SEQ ID NO: 1) or AKYAKEXXXAXX EIXXLPNLTX XQXXAFIXKL XDDPSQSSEL LSEAKKLNDS Q (SEQ ID NO:2), wherein each X individually corresponds to an amino acid residue which is varied in the population are disclosed. Also populations of polynucleotides, wherein each member encodes a member of a polypeptide population are disclosed. Furthermore, combinations of such polypeptide populations and such polynucleotide populations are disclosed, wherein each member of polypeptide population is physically or spatially associated with the polynucleotide encoding that member via means for genotype-phenotype coupling.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: October 18, 2016
    Assignee: AFFIBODY AB
    Inventors: Lars Abrahmsén, Nina Herne, Christofer Lendel, Joachim Feldwisch
  • Patent number: 9447127
    Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: September 20, 2016
    Assignees: University of Rochester, The Los Angeles Biomedical Research Institute of Harbor-UCLA Medical Center, University of Guelph
    Inventors: Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J Waring, Frans Walther, Larry M. Gordon
  • Patent number: 9446145
    Abstract: The invention relates to curcumin derivatives having the formula I: wherein: Z represents: H3CO A represents —CH2—CH2— or —CH?CH—; L represents —C(O)—(NH)n1—R—(NH)n2—C(O)—; R represents a saturated or unsaturated, branched or unbranched hydrocarbyl chain having a minimum of 3 carbon atoms in the chain; wherein the maximum number of carbon atoms in the chain is 24; and wherein the carbon atoms of the chain can be replaced by at least one heteroatom, wherein the heteroatoms are independently —O— or —NH2—, with the proviso that each heteroatom is separated from each other heteroatom by at least two carbon atoms; n1 and n2 independently represent 0 or 1; and Y represents an antibody that binds specifically to a target antigen of a tumor cell. The invention further relates to methods of method of inhibiting the growth of tumors in a human by administering an effective amount of the curcumin derivative, and to methods of producing the curcumin derivative.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: September 20, 2016
    Inventors: Probal Banerjee, Raja Krishnaswami
  • Patent number: 9435809
    Abstract: The present invention relates to methods and compositions for treating and reducing the risk of Acute Myelogenous Leukemia (AML). In particular, the invention provides methods for identifying novel treatments for AML based on reproducible and detectable changes in AML1-ETO acetylation. The present invention further provides methods of using these treatments.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: September 6, 2016
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Stephen D. Nimer, Lan Wang
  • Patent number: 9421255
    Abstract: The present invention is directed to an inventive composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid sequence, complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and/or a nucleic acid sequence encoding said antigen; and c) a carrier molecule for combined packaging the adjuvant component and the antigen. The present invention is also directed to the first medical use of such an inventive composition or vaccine composition and to the second medical use of such an inventive composition or vaccine composition or components thereof for the treatment of diseases, such as infectious or cancer or tumor diseases as defined herein. The present invention furthermore discloses kits comprising such a composition or vaccine composition.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: August 23, 2016
    Assignee: CureVac AG
    Inventors: Patrick Baumhof, Karl-Josef Kallen, Mariola Fotin-Mleczek
  • Patent number: 9371363
    Abstract: The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino acids in the amino sequence of said peptide are the same, for use as antibacterial agents.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: June 21, 2016
    Assignee: Novabiotics Limited
    Inventor: Deborah O'Neil